NYSE · PACS

PACS Group, Inc.

$47.08 +$0.23 (+0.49%) 1D After hours

Key Metrics

$7.42B
Market cap
30.42×
P/E · TTM
$5.43B
Revenue · TTM
$243.77M
Net income
EPS · TTM $1.46
Dividend yield
Free cash flow
Beta · 1Y 1.38
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 12
    The stock moved +28.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 12
  • Mar 30
    From its Feb 26 high, the share price fell 27%.

    Peak close $41.67 on Feb 26; trough close $30.38 on Mar 30. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -27%
  • Feb 27
    The stock moved -12.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 27

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$7.42B
Enterprise value$7.42B
Shares outstanding158.3M
52-wk range$7.50 – $48.00
Avg volume · 20D902.8K
Net cash −$218.00K
Book value / share$6.23
IndustryServices-Skilled Nursing Care Facilities
ExchangeNYSE
About PACS Group, Inc.
IPO dateApr 11, 2024
Employees47455

PACS Group Inc is a post-acute healthcare company mainly focused on delivering skilled nursing care through a portfolio of independently operated facilities.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E30.42
P/S1.37
P/FCF
EV/EBITDA
EV/Sales1.37
Graham №$14.33

Profitability

Gross
Operating 6.5%
Net 4.5%
FCF
ROE / ROIC 27.9% · 23.5%

Financial Health

Current ratio0.99
Quick ratio
Debt / equity0.24
Debt / EBITDA
Net cash −$218.00K
Working capital−$5.42M

Cash Flow · TTM

Operating CF $490.32M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

7 / 9
Strong fundamentals · 7 of 9 signals passing

Altman Z-Score

2.2
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

$14.33 vs $47.08
Trades 3.3× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings